These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38738667)

  • 1. The Effect of Ophthalmic Antibiotics on Clinical Outcomes and Transmissibility of Conjunctivitis Associated with Haemophilus influenzae versus Other Pathogens: Secondary Analysis of a Randomized Controlled Trial.
    Thomas ET; Perera-Salazar R; Frost HM
    J Pediatric Infect Dis Soc; 2024 Jul; 13(7):349-351. PubMed ID: 38738667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
    Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
    Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic antibiotics for treatment of the conjunctivitis-otitis media syndrome.
    Bodor FF
    Pediatr Infect Dis J; 1989 May; 8(5):287-90. PubMed ID: 2631693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctivitis in infants and children.
    Wald ER
    Pediatr Infect Dis J; 1997 Feb; 16(2 Suppl):S17-20. PubMed ID: 9041623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era.
    Buznach N; Dagan R; Greenberg D
    Pediatr Infect Dis J; 2005 Sep; 24(9):823-8. PubMed ID: 16148850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
    DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM
    PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
    Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
    J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic antibiotic therapy for relapsing Haemophilus influenzae conjunctivitis.
    Hwang DG
    Am J Ophthalmol; 1993 Jun; 115(6):814-6. PubMed ID: 8506920
    [No Abstract]   [Full Text] [Related]  

  • 10. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
    Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
    Williams L; Malhotra Y; Murante B; Laverty S; Cook S; Topa D; Hardy D; Wang H; Gigliotti F
    J Pediatr; 2013 Apr; 162(4):857-61. PubMed ID: 23092529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominant role of Haemophilus influenzae in the association of conjunctivitis, acute otitis media and acute bacterial paranasal sinusitis in children.
    Hu YL; Lee PI; Hsueh PR; Lu CY; Chang LY; Huang LM; Chang TH; Chen JM
    Sci Rep; 2021 Jan; 11(1):11. PubMed ID: 33420151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL; Paterno MR; Usner DW; Pichichero ME
    Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
    Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of bacterial conjunctivitis in children.
    Patel PB; Diaz MC; Bennett JE; Attia MW
    Acad Emerg Med; 2007 Jan; 14(1):1-5. PubMed ID: 17119185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management.
    Leung AKC; Hon KL; Wong AHC; Wong AS
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):120-127. PubMed ID: 29380707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.